Befesa Narrows FY2026 Adjusted EBITDA Guidance to €260M–€270M
Befesa gives FY2026 adjusted EBITDA guidance of €286M–€296M including a US grant.
Related stories
Eli Lilly Raises Revenue Forecast as Shares Surge
Higher revenue guidance offsets weaker-than-expected results for its weight-loss injections and Foundayo.
M impact | EARNINGS | Oct 29, 2026, 02:13 PM UTC
Eli Lilly Raises Revenue Outlook as Weight-Loss Shots Offset Foundayo Sales Miss
Eli Lilly raised its revenue outlook, with weight-loss shot sales offsetting a Foundayo sales miss; its shares jumped.
M impact | EARNINGS | Oct 29, 2026, 02:12 PM UTC
Bristol Myers Squibb Sees FY Adjusted Revenue at $49.75B-$50.25B
M impact | EARNINGS | Oct 29, 2026, 02:12 PM UTC
TSX Slips on Mining Losses
The S&P/TSX Composite Index slipped below 36,500 on Thursday, weighed down by losses in the mining sector as falling gold prices pressured major producers. Agnico Eagle fell nearly
H impact | EARNINGS | Oct 29, 2026, 02:08 PM UTC
Indegene Reports September-Quarter Revenue of 11.22 Billion Rupees
L impact | EARNINGS | Oct 29, 2026, 02:08 PM UTC
Indegene Reports September-Quarter Consolidated Net Profit of 1.12 Billion Rupees
M impact | EARNINGS | Oct 29, 2026, 02:08 PM UTC